Skip to main content

Idiopathic Immune Complex Glomerulonephritis

  • Reference work entry
  • First Online:
Glomerulonephritis

Abstract

Immune complex glomerulonephritis (GN) is characterized by the presence of immune complexes in the glomerulus, typically detected by immunofluorescence microscopy and containing both immunoglobulin and complement components. These complexes trigger complement activation and inflammatory cell recruitment, leading to glomerular injury. By light microscopy, the histologic pattern is often that of membranoproliferative GN. A variety of diverse conditions have been associated with immune complex GN, including chronic infections, hematologic disease, and autoimmunity. The history of this condition reveals that over the past several decades, an increasing portion of disease originally thought to be “idiopathic” has had its underlying cause identified. Thus true idiopathic immune complex GN, in which no identifiable cause is found, is increasingly rare and should be considered a diagnosis of exclusion. The finding of an unexplained immune complex GN should prompt a thorough search for an associated systemic disease, especially hepatitis C infection, hematological malignancy, and collagen vascular diseases such as systemic lupus erythematosus. In the absence of an underlying cause, treatment is based on maintaining glomerular health with blood pressure control and proteinuria reduction, while aggressive cases require immune suppression to decrease immune complex formation and the subsequent inflammatory cascade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 599.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N (2016) Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. BMC Nephrol 17:7. https://doi.org/10.1186/s12882-015-0219-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bagheri N, Nemati E, Rahbar K, Nobakht A, Einollahi B, Taheri S (2008) Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med 11(1):26–29. https://doi.org/08111/AIM.008

  • Bergstein JM, Andreoli SP (1995) Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. Pediatr Nephrol 9(3):268–271

    Article  CAS  PubMed  Google Scholar 

  • Bhat P, Weiss S, Appel GB, Radhakrishnan J (2007) Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases. Am J Kidney Dis 50(4):641–644. https://doi.org/10.1053/j.ajkd.2007.05.027

    Article  CAS  PubMed  Google Scholar 

  • Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ (2002) Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347(2):103–109. https://doi.org/10.1056/NEJMoa013036

    Article  PubMed  Google Scholar 

  • Cattran DC, Cardella CJ, Roscoe JM, Charron RC, Rance PC, Ritchie SM, Corey PN (1985) Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 27(2):436–441

    Article  CAS  PubMed  Google Scholar 

  • Chapman SJ, Cameron JS, Chantler C, Turner D (1980) Treatment of mesangiocapillary glomerulonephritis in children with combined immunosuppression and anticoagulation. Arch Dis Child 55(6):446–451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC (2012) Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin Nephrol 77(4):290–295

    Article  CAS  PubMed  Google Scholar 

  • Donadio JV Jr, Offord KP (1989) Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 14(6):445–451

    Article  PubMed  Google Scholar 

  • Donadio JV Jr, Anderson CF, Mitchell JC 3rd, Holley KE, Ilstrup DM, Fuster V, Chesebro JH (1984) Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med 310(22):1421–1426. https://doi.org/10.1056/NEJM198405313102203

    Article  PubMed  Google Scholar 

  • Emre S, Sirin A, Alpay H, Tanman F, Uysal V, Nayir A, Bilge I (1995) Pulse methylprednisolone therapy in children with membranoproliferative glomerulonephritis. Acta Paediatr Jpn 37(5):626–629

    Article  CAS  PubMed  Google Scholar 

  • Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E (1994) Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 67(1):59–65

    Article  CAS  PubMed  Google Scholar 

  • Fogo AB (2006) Fundamentals of renal pathology. Springer, New York

    Google Scholar 

  • Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, Noel LH, Callard P, Delahousse M, Ronco P (2011) Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 6(7):1609–1616. https://doi.org/10.2215/CJN.10611110

    Article  CAS  PubMed  Google Scholar 

  • Haddad M, Lau K, Butani L (2007) Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol 22(10):1787–1791. https://doi.org/10.1007/s00467-007-0523-1

    Article  PubMed  Google Scholar 

  • Hanko JB, Mullan RN, O’Rourke DM, McNamee PT, Maxwell AP, Courtney AE (2009) The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 24(10):3050–3054. https://doi.org/10.1093/ndt/gfp254

    Article  PubMed  Google Scholar 

  • Harmankaya O, Basturk T, Ozturk Y, Karabiber N, Obek A (2001) Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol 33(3):583–587

    Article  CAS  PubMed  Google Scholar 

  • Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE et al (1993) Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328(7):465–470. https://doi.org/10.1056/NEJM199302183280703

    Article  CAS  PubMed  Google Scholar 

  • Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A (2004) Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 19(12):3160–3164. https://doi.org/10.1093/ndt/gfh526

    Article  PubMed  Google Scholar 

  • Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ (2006) Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 69(3):504–511. https://doi.org/10.1038/sj.ki.5000084

    Article  CAS  PubMed  Google Scholar 

  • Lorenz EC, Sethi S, Leung N, Dispenzieri A, Fervenza FC, Cosio FG (2010) Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 77(8):721–728. https://doi.org/10.1038/ki.2010.1

    Article  PubMed  Google Scholar 

  • McGrogan A, Franssen CF, de Vries CS (2011) The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 26(2):414–430. https://doi.org/10.1093/ndt/gfq665

    Article  PubMed  Google Scholar 

  • Ponticelli C, Glassock RJ (2010) Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 5(12):2363–2372. https://doi.org/10.2215/CJN.06720810

    Article  PubMed  Google Scholar 

  • Segarra A, Amoedo ML, Martinez Garcia JM, Pons S, Praga M, Garcia EI, Alonso JC, Gasco JM, Pou L, Piera L (2007) Efficacy and safety of ‘rescue therapy’ with mycophenolate mofetil in resistant primary glomerulonephritis – a multicenter study. Nephrol Dial Transplant 22(5):1351–1360. https://doi.org/10.1093/ndt/gfl805

    Article  CAS  PubMed  Google Scholar 

  • Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grunfeld JP, Niaudet P, Lesavre P, Fremeaux-Bacchi V (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82(4):454–464. https://doi.org/10.1038/ki.2012.63

    Article  CAS  PubMed  Google Scholar 

  • Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis – a new look at an old entity. N Engl J Med 366(12):1119–1131. https://doi.org/10.1056/NEJMra1108178

    Article  CAS  PubMed  Google Scholar 

  • Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, Fervenza FC (2010) Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 5(5):770–782. https://doi.org/10.2215/CJN.06760909

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr (1992) Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone – a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 6(2):123–130

    Article  CAS  PubMed  Google Scholar 

  • Vilayur E, Trevillian P, Walsh M (2009) Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol 5(1):54–58. https://doi.org/10.1038/ncpneph0989

    Article  CAS  PubMed  Google Scholar 

  • Woo KT, Chan CM, Chin YM, Choong HL, Tan HK, Foo M, Anantharaman V, Lee GS, Chiang GS, Tan PH, Lim CH, Tan CC, Lee E, Tan HB, Fook-Chong S, Lau YK, Wong KS (2010) Global evolutionary trend of the prevalence of primary glomerulonephritis over the past three decades. Nephron Clin Pract 116(4):c337–c346. https://doi.org/10.1159/000319594

    Article  PubMed  Google Scholar 

  • Yuan M, Zou J, Zhang X, Liu H, Teng J, Zhong Y, Ding X (2010) Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis. Clin Nephrol 73(5):354–359

    Article  CAS  PubMed  Google Scholar 

  • Zauner I, Bohler J, Braun N, Grupp C, Heering P, Schollmeyer P (1994) Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol Dial Transplant 9(6):619–622

    Article  CAS  PubMed  Google Scholar 

  • Zimmerman SW, Moorthy AV, Dreher WH, Friedman A, Varanasi U (1983) Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med 75(6):920–927

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Renu Regunathan-Shenk .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Regunathan-Shenk, R., Canetta, P.A. (2019). Idiopathic Immune Complex Glomerulonephritis. In: Trachtman, H., Herlitz, L., Lerma, E., Hogan, J. (eds) Glomerulonephritis. Springer, Cham. https://doi.org/10.1007/978-3-319-49379-4_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-49379-4_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-49378-7

  • Online ISBN: 978-3-319-49379-4

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics